Welcome to our dedicated page for IBEX SEC filings (Ticker: IBEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IBEX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IBEX's regulatory disclosures and financial reporting.
IBEX Ltd (IBEX) Form 4 filing discloses two open-market sales by Chief Executive Officer and Director Robert Thomas Dechant on 2 and 3 July 2025. The transactions involved a total of 5,000 common shares sold at $30.00 per share, producing proceeds of roughly $150,000. Following the dispositions, Dechant’s direct ownership declined from 198,633 to 193,633 shares, a reduction of about 2.5% of his previously held stake. No derivative security activity was reported, and the filing was submitted individually on 3 July 2025.
The modest size of the sale relative to Dechant’s remaining holdings suggests routine portfolio management rather than a wholesale change in insider sentiment. Nonetheless, any CEO sale can attract investor attention, particularly when not explicitly tied to a pre-arranged 10b5-1 trading plan (the form does not indicate such a plan was in place).